Indegene Limited IPO
Introduction
Indegene Limited, a pioneering force in digital services for the life sciences industry, is set to embark on a significant milestone with its Initial Public Offering (IPO). Established in 1998, the company has been instrumental in providing crucial support across various facets of pharmaceutical and healthcare operations.
Company Profile Indegene Limited offers an extensive array of digital solutions tailored to meet the intricate demands of the life sciences sector. Their services encompass every stage of the pharmaceutical lifecycle, including drug development, clinical trials, regulatory compliance, and marketing support. With a robust portfolio, Indegene has positioned itself as a trusted partner for industry leaders seeking innovative solutions. Service Offerings
Enterprise Commercial Solutions: Streamlining commercial operations through advanced digital platforms.
Omnichannel Activation: Enhancing customer engagement and brand visibility across multiple channels.
Enterprise Medical Solutions: Facilitating seamless medical affairs management and compliance.
Enterprise Clinical Solutions and Consultancy: Providing strategic guidance and support throughout the clinical development process.
Subsidiary: DT Associates Limited
Under the umbrella of Indegene Limited, DT Associates Limited operates as a consultancy arm specializing in digital transformation within the life sciences domain. Through its brand, "DT Consulting," the subsidiary assists companies in navigating the complexities of digital evolution, ensuring sustained growth and competitiveness.
Accolades and Recognitions
Indegene Limited's commitment to excellence has been duly recognized, exemplified by the prestigious Platinum Level award received at the 2023 Healthy Workplace Conference and Awards. This accolade underscores the company's dedication to fostering a healthy and vibrant work environment, in alignment with global standards of excellence.
Objectives of the Issue The IPO proceeds are earmarked for strategic initiatives aimed at fortifying Indegene Limited's position in the market. Key objectives include:
Debt Repayment: Addressing indebtedness within Material Subsidiaries to optimize financial stability.
Capital Expenditure: Funding essential capital requirements to support operational expansion and innovation.
General Corporate Purposes: Utilizing funds for organic growth initiatives and potential acquisitions to bolster market presence.
Indegene Limited IPO: Key Details
IPO Dates: 6 to 8 May 2024
Price Band: ₹430 to ₹452 per share
Lot Size: 33 Shares
Issue Size: 1,841.76 Crs
Retail Quota: 35%
GMP: +55% (Only for information)
Link for joining Whatsapp Group for Trading/Investment Ideas:
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.